Related references
Note: Only part of the references are listed.Clinical Utility of YKL-40 in Polymyositis/dermatomyositis-associated Interstitial Lung Disease
Hironao Hozumi et al.
JOURNAL OF RHEUMATOLOGY (2017)
Clinical significance of soluble CD163 in polymyositis-related or dermatomyositis-related interstitial lung disease
Yasunori Enomoto et al.
ARTHRITIS RESEARCH & THERAPY (2017)
The clinical utility of serum IL-35 in patients with polymyositis and dermatomyositis
Liguo Yin et al.
CLINICAL RHEUMATOLOGY (2016)
Elevated Serum Levels of Soluble CD163 in Polymyositis and Dermatomyositis: Associated with Macrophage Infiltration in Muscle Tissue
Qing-Lin Peng et al.
JOURNAL OF RHEUMATOLOGY (2015)
AN OVERVIEW OF POLYMYOSITIS AND DERMATOMYOSITIS
Andrew R. Findlay et al.
MUSCLE & NERVE (2015)
B-cell activating factor as a serological biomarker for polymyositis and dermatomyositis
Qing-Lin Peng et al.
BIOMARKERS IN MEDICINE (2014)
Immune mechanisms in polymyositis and dermatomyositis and potential targets for therapy
Paulius Venalis et al.
RHEUMATOLOGY (2014)
Cancer risk by combined levels of YKL-40 and C-reactive protein in the general population
K. H. Allin et al.
BRITISH JOURNAL OF CANCER (2012)
Can YKL-40 be a new inflammatory biomarker in cardiovascular disease?
Jens Kastrup
IMMUNOBIOLOGY (2012)
Idiopathic inflammatory myositis-associated interstitial lung disease: ethnicity differences and lung function trends in a British cohort
Felix Chua et al.
RHEUMATOLOGY (2012)
Soluble CD163
Holger J. Moller
SCANDINAVIAN JOURNAL OF CLINICAL & LABORATORY INVESTIGATION (2012)
Therapy of polymyositis and dermatomyositis
Isabelle Marie et al.
AUTOIMMUNITY REVIEWS (2011)
Plasma YKL-40 levels in healthy subjects from the general population
Stig E. Bojesen et al.
CLINICA CHIMICA ACTA (2011)
IL-6, but not TNF-α, increases plasma YKL-40 in human subjects
Anders R. Nielsen et al.
CYTOKINE (2011)
Polymyositis and Dermatomyositis: Pathophysiology
Kanneboyina Nagaraju et al.
RHEUMATIC DISEASE CLINICS OF NORTH AMERICA (2011)
Elevated Plasma YKL-40 Levels and Ischemic Stroke in the General Population
Alisa D. Kjaergaard et al.
ANNALS OF NEUROLOGY (2010)
Increased YKL-40 expression in patients with carotid atherosclerosis
Annika E. Michelsen et al.
ATHEROSCLEROSIS (2010)
YKL-40: a new biomarker in cardiovascular disease?
Anders Bruun Mathiasen et al.
BIOMARKERS IN MEDICINE (2010)
Adult clinically amyopathic dermatomyositis with rapid progressive interstitial lung disease: a retrospective cohort study
Shuang Ye et al.
CLINICAL RHEUMATOLOGY (2007)
Circulating YKL-40 levels during human endotoxaemia
JS Johansen et al.
CLINICAL AND EXPERIMENTAL IMMUNOLOGY (2005)
International consensus outcome measures for patients with idiopathic inflammatory myopathies. Development and initial validation of myositis activity and damage indices in patients with adult onset disease
DA Isenberg et al.
RHEUMATOLOGY (2004)
Polymyositis and dermatomyositis
MC Dalakas et al.
LANCET (2003)
Serum human cartilage glycoprotein 39 as a marker of arthritis associated with inflammatory bowel disease
L Punzi et al.
ANNALS OF THE RHEUMATIC DISEASES (2003)
Raised human cartilage glycoprotein-39 plasma levels in patients with rheumatoid arthritis and other inflammatory conditions
K Vos et al.
ANNALS OF THE RHEUMATIC DISEASES (2000)
Share Paper
